INDIANAPOLIS – Eli Lilly and Company announced today that the U.S. Food and Drug Administration approved a label expansion for Zepbound (tirzepatide), now including the four-dose single-patient-use KwikPen, which provides a full month of treatment in one device. With the Zepbound KwikPen, Lilly is offering more options and helping ensure patients and healthcare providers can choose the best solution for their individual needs, preferences, and circumstances. Patients, with a valid prescription and opting for self-pay through LillyDirect, can receive all doses of Zepbound either in a KwikPen or a single-dose vial, starting at $299 per month for the 2.5 mg dose.1,2
“Zepbound is the #1 prescribed injectable obesity‑management medication,3 helping adults achieve meaningful and clinically proven weight loss, on average, up to 50 pounds as seen in SURMOUNT-5,” said Ilya Yuffa, executive vice president and president of Lilly USA and Global Customer Capabilities. “As part of our commitment to supporting people living with obesity in their weight management journey, we are introducing a new option with the Zepbound KwikPen, a device trusted by patients globally and in the United States for other Lilly medicines.”
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect,4 which offers self-pay pricing at a 50% or greater discount compared to the list price of other incretin (GLP-1) medicines for obesity. One out of every three new patients starting a branded weight management medication was prescribed Zepbound self-pay vials in 2025,5 reflecting strong demand for this innovative access model and Lilly’s commitment to supporting patients with obesity.
“After trying so many times to lose weight over the years, I’m grateful I talked to my doctor about Zepbound,” said Jacob M., Zepbound patient and LillyDirect customer. “Along with diet and exercise, Zepbound has helped me make real, lasting progress. And LillyDirect made getting the medicine simple, from filling my prescription to home delivery. I feel supported at every step of my weight loss journey.”
The demand for Zepbound highlights its strong efficacy profile. In the SURMOUNT-1 trial, adults taking Zepbound 15 mg lost an average of 20.9% of their body weight over 72 weeks, compared to 3.1% with placebo. In the SURMOUNT-5 open-label study, people who took Zepbound on average lost 50 lbs (20.2% weight loss), compared with people who took injectable Wegovy, who on average lost 33 lbs (13.7% weight loss). See additional data here.
To learn more about Zepbound and KwikPen, visit Lilly.com/lillydirect/medicines/zepbound?device=kwikpen.
Zepbound is an injectable prescription medicine that may help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off. Zepbound may also help adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known whether Zepbound is safe and effective for use in children.
Zepbound is available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg doses. The 2.5 mg is a starting dose and not an approved maintenance dose. The recommended maintenance doses are 5 mg, 10 mg, or 15 mg injected subcutaneously once per week for weight reduction and long-term maintenance. The recommended maintenance doses for OSA are 10 mg or 15 mg.
Individual results vary. Zepbound is not for cosmetic weight loss. Zepbound may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing or shortness of breath. If you have any of these symptoms, tell your health care provider. Do not use Zepbound if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC). Do not use Zepbound if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Do not use Zepbound if you have had a serious allergic reaction to tirzepatide or any of its ingredients.
Submit Your Press Release
Have news to share? Send us your press releases and announcements.
Send Press Release
